Tight Disease Control in Early RA

Rheumatic Disease Clinics of North America

Volumn 38, Issue 2, 2012, Pages 327-343

  Sen, Deepali ^a   Brasington, Richard ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Early RA; Rheumatoid arthritis; Tight control; Treatment

Indexed keywords

ADALIMUMAB; AURANOFFIN; AZATHIOPRINE; BIOLOGICAL PRODUCT; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PENICILLAMINE; PLACEBO; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; HUMAN; LOW DRUG DOSE; PATIENT MONITORING; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; HEALTH STATUS; HUMANS; JOINTS; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX;

EID: 84864009260     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2012.04.004     Document Type: Review

References (57)

1. van Der Heijde D. Joint erosions in patients with early rheumatoid arthritis. Br J Rheumatol 1995, 34:74-78.
2. Machold K., Stamm T., Eberl G., et al. Very recent onset arthritis clinical, laboratory and radiologic findings during the first year of disease. J Rheumatol 2002, 29:2278-2287.
3. Giles J., Post W., Blumenthal R., et al. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2011, 63:3216-3225.
4. Nielen M., Van Schaardenberg D., Reesink H., et al. Specific auto antibodies precede the symptoms of rheumatoid arthritis -a study of serial measurements in blood donors. Arthritis Rheum 2004, 50:350-356.
5. Lard L., Visser H., Speyer I., et al. Early versus delayed treatment in patients with recent onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001, 111:446-451.
6. Anderson J., Wells G., Verhoeven A., et al. Factors predicting response to rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000, 43:22-29.
7. Quinn M., Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003, 21:S154-S157.
8. Aletaha G., Eberl G., Nell V., et al. Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. Ann Rheum Dis 2002, 61:630-634.
9. Aletaha D., Neogi T., Silman A., et al. 2010 Rheumatoid arthritis classification criterion a ACR/EULAR collaborative initiative. Arthritis Rheum 2010, 62:2569-2581.
10. Pinals R., Masi A., Larsen R., et al. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981, 24:1308-1315.
11. Smolen J., Aletaha D., Bijlsma J., et al. Treating rheumatoid arthritis to target: recommendation of a international task force. Ann Rheum Dis 2010, 69:631-637.
12. van der Heijde D., van't Hof M., van Riel P., et al. Judging disease activity in clinical practice in RA: first step to developing a disease activity score. Ann Rheum Dis 1990, 49:916-920.
13. Prevoo M., van't Hof M., Kuper H., et al. Modified disease activity scores that include 28 joint counts. Arthritis Rheum 1998, 38:44-48.
14. Felson D., Anderson J., Boers M., et al. American College of Rheumatology, preliminary definition of improvement in RA. Arthritis Rheum 1995, 38:727-735.
15. van Gestel A., Prevoo M., van't Hof M., et al. Development and validation of EULAR response criterion for RA. Comparison with preliminary ACR and WHO/International League Against Rheumatism criterion. Arthritis Rheum 1996, 39:34-40.
16. Smolen J., Breedveld F., Schiff M., et al. A simplified disease activity index in rheumatoid arthritis for use in clinical practice. Rheumatology 2003, 42:244-257.
17. Aletaha D., Nell V., Stamm T., et al. Acute phase reactant adds little to composite disease activity indices for rheumatoid arthritis. Validation of a clinical activity score. Arthritis Res Ther 2005, 7:R796-R806.
18. Pincus T., Swearingen C., Bergmen M., et al. "Routine assessment of patient index data 3" RAPID 3 a rheumatoid arthritis index without formal joint count for routine care: proposed severity categories compared to disease activity scores and clinical disease activity index categories. J Rheumatol 2008, 35:2136-2147.
19. Wells G., Boers M., Shea B., et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005, 32:2016-2024.
20. Wells G., Boers M., Shea B., et al. Low disease activity state workshop: low disease activity in rheumatoid arthritis. J Rheumatol 2003, 30:1110-1111.
21. Khanna D., Oh M., Furst D., et al. Evaluation of minimal disease activity and remission in early seropositive rheumatoid arthritis. Arthritis Rheum 2007, 57:440-447.
22. Egsmose C., Lund B., Borg G., et al. Patients with rheumatoid arthritis benefit from early second line therapy. J Rheumatol 1995, 22:2208-2213.
23. Matteson E., Weyland C., Fulbright J., et al. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with non response to non aggressive DMARD treatment and perspective from a 2-yr open label trial. Rheumatology 2004, 43:619-625.
24. Bakker M., Jacobs J., Welsing P., et al. Early clinical response to treatment predicts 5 year outcome in RA patients. Ann Rheum Dis 2011, 70:1099-1103.
25. Nell V., Machold K., Ebler G., et al. Benefit of very early referral and very early therapy with disease modifying anti rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004, 43:906-914.
26. Mottonen T., Hannonen P., Leirisalo-Repo M., et al. Comparison of combination therapy and single drug therapy in early RA. Lancet 1999, 353:1568-1573.
27. Rantalaiho V., Korpela M., Laasone L., et al. Early combination disease modifying anti-rheumatic therapy and tight control improve long term radiologic outcome in patients with early RA. Arthritis Res Ther 2010, 12:R122.
28. Rantaliaho V., Korpela M., Haanonen P., et al. The good initial response to therapy with a combination of traditional disease modifying anti-rheumatic drugs is sustained over time. Arthritis Rheum 2009, 60:1222-1231.
29. Maini R., Breedveld F., Kalden J., et al. Sustained improvement over two years in physical function structural damage and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004, 50:1051-1065.
30. Breedveld F., Emery P., Keystone E., et al. Infliximab in active early RA. Ann Rheum Dis 2004, 63:149-155.
31. Breedveld F., Weismann M., Kavanaugh A., et al. The PREMIER Study. Arthritis Rheum 2006, 54:26-37.
32. Genovese M., Bathon J., Martin R., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis. Arthritis Rheum 2002, 46:1443-1450.
33. Baumgartner S., Fleischmann R., Moreland L., et al. Etanercept in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. J Rheumatol 2004, 31:1532-1537.
34. Smolen J., van der Heijde D., St Clair E., et al. Predictors of joint damage in patients treated with high dose methotrexate with or without concomitant infliximab. Arthritis Rheum 2006, 54:702-710.
35. Smolen J., Han C., van der Heijde D., et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab with methotrexate. Ann Rheum Dis 2009, 68:323-327.
36. Van der Heijde D., Landewe R., Klareskog L., et al. Presentation and analysis of data on radiographic outcome in clinical trials. Arthritis Rheum 2005, 52:49-60.
37. Grigor C., Capell H., Stirling A., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study). Lancet 2004, 364:263-269.
38. Boers M., Verhoeven A., Markusse H., et al. Randomized comparison of combined step down prednisone, methotrexate and sulfasalazine with sulfasalazine alone in early rheumatoid arthritis. Lancet 1997, 350:309-318.
39. van Tuyl L., Lems W., Voskuyl A., et al. Tight control and intensified COBRA combination treatment in early RA. Ann Rheum Dis 2008, 67:1574-1577.
40. Goekoop-Ruiterman Y., deVries-Bouwstra J., Allart C., et al. Comparison of treatment strategies in early RA. Ann Intern Med 2007, 146:406-415.
41. van der Bijl A., Goekoop-Ruiterman Y., deVries-Bouwstra J., et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2007, 56:2129-2134.
42. Moreland L., O'Dell J., Paulus C., et al. Two year radiographic results from the TEAR trial. Arthritis Rheum 2010, 62(Suppl 10):1368. [abstract].
43. Moreland L., O'Dell J., Paulus C., et al. TEAR: Treatment of Early Aggressive RA: a randomized, double-blind, 2-year trial comparing immediate triple DMARD versus methotrexate plus etanercept to step-up from initial methotrexate monotherapy. Arthritis Rheum 2009, 60(Suppl 10):1895. [abstract].
44. van Vollenhoven R., Ernestam S., Geborek P., et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine in patients with early rheumatoid arthritis. Lancet 2009, 374:459-466.
45. Vermeer M., Kuper H., Hoekstra M., et al. Implementation of a treat to target strategy in very early RA. Arthritis Rheum 2011, 63:2865-2872.
46. von Eijk I., Nielan M., van der Horst-Bruinsma I., et al. Aggressive therapy in patients with early arthritis results in similar outcome compared to conventional care. Rheumatology 2012, 51:646-694.
47. van Dongen H., van Aken J., Lard L., et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis. Arthritis Rheum 2007, 56:1424-1432.
48. van der Linden M., Knevel R., Huizinga T., et al. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum 2011, 63:37-42.
49. Sokka T., Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 2003, 30:1138-1146.
50. Sokka T., Hetland M., Makinen H., et al. Remission and rheumatoid arthritis data in patients receiving usual care in 24 countries. Arthritis Rheum 2008, 58:2642-2651.
51. Pincus T., Seguardo O. Most visits of most patients with rheumatoid arthritis to most rheumatologist do not include a formal quantitative joint count. Ann Rheum Dis 2007, 65:820-822.
52. Pincus T., Swearingen C., Bergman M., et al. RAPID 3 on a MDHAQ: agreement with DAS 28 and CDAI activity categories, scored in 5 versus more than 90 seconds. Arthritis Care Res 2010, 62:181-189.
53. Molenaar E., Voskuyl A., Dinant H., et al. Progression of radiologic damage in RA in patients with clinical remission. Arthritis Rheum 2004, 50:36-42.
54. Cohen G., Gossec L., Dougados M., et al. Radiologic damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis 2007, 66:358-363.
55. Naredo E., Collado P., Cruz A., et al. Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive valve in disease activity and radiologic progression. Arthritis Rheum 2007, 57:116-124.
56. Hetland M., Ejbjerg B., Horslev-Pertesen K., et al. MRI bone edema is the strongest predictor of subsequent radiographic progression. Ann Rheum Dis 2009, 68:384-390.
57. Brown A., Conaghan P., Karim Z., et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008, 58:2958-2967.